Innovative therapeutics

Investors

BioMarin Completes Ascent Pediatrics Transaction
May 18, 2004
PRNewswire-FirstCall
NOVATO, Calif.

BioMarin Pharmaceutical Inc. announced that it has completed the transaction, announced April 20, 2004, to obtain Ascent Pediatrics, a profitable pediatrics business that includes Orapred(R), the top selling drug in its class for treatment of asthma in children, and the national field force that currently calls upon pediatricians throughout the United States.

BioMarin develops innovative biopharmaceutical products and commercializes therapeutics for serious pediatric diseases.

BioMarin's press releases and other company information are available online at http://www.bmrn.com/ . Information on BioMarin's website is not incorporated by reference into this press release.

NOTE: Orapred is a registered trademark of Ascent Pediatrics, Inc., a wholly owned subsidiary of Medicis Pharmaceutical Corporation.

   Contacts:

   Joshua A. Grass                Susan Ferris
   Sr. Manager, Investor and      Manager, Corporate Communications
    Financial Relations           BioMarin Pharmaceutical Inc.
   BioMarin Pharmaceutical Inc.   415-506-6701
   415-506-6777

SOURCE: BioMarin Pharmaceutical Inc.

CONTACT: Joshua A. Grass, Sr. Manager, Investor and Financial Relations,
+1-415-506-6777, or Susan Ferris, Manager, Corporate Communications,
+1-415-506-6701, both of BioMarin Pharmaceutical Inc.


BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq®
Brineura®
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information